

Joe Lombardo  
Governor

Richard Whitley, MS  
Director



# DEPARTMENT OF HEALTH AND HUMAN SERVICES

DIVISION OF HEALTH CARE FINANCING AND POLICY

*Helping people. It's who we are and what we do.*



Stacie Weeks,  
JD MPH  
Administrator

---

*Si quiere este documento traducido, por favor escriba a [dhcftp@dhcftp.nv.gov](mailto:dhcftp@dhcftp.nv.gov)  
如果希望获得本文件的翻译版本, 请提交申请至 [dhcftp@dhcftp.nv.gov](mailto:dhcftp@dhcftp.nv.gov)*

## NOTICE OF MEETING TO SOLICIT PUBLIC COMMENTS AND INTENT TO ACT UPON AMENDMENTS TO THE NEVADA MEDICAID SERVICES MANUAL (MSM)

### AGENDA

<b>Date of Publication:</b>	March 23, 2023
<b>Date and Time of Meeting:</b>	April 25, 2023, at 10:05 AM or upon completion of the amendments to the State Plan for Medicaid Services Public Hearing immediately preceding this meeting at the same location(s)
<b>Name of Organization:</b>	The State of Nevada, Department of Health and Human Services (DHHS), Division of Health Care Financing and Policy (DHCFP)
<b>Place of Meeting:</b>	DHCFP 1100 East William Street First Floor Conference Room Carson City, Nevada 89701

Please use the teleconference/Microsoft Teams options provided below. If accommodations are requested, please advise using the information at the end of this agenda.

*Note: If at any time during the meeting an individual who has been named on the agenda or has an item specifically regarding them included on the agenda is unable to participate because of technical or other difficulties, please email Jenifer Graham at [documentcontrol@dhcftp.nv.gov](mailto:documentcontrol@dhcftp.nv.gov) and note at what time the difficulty started so that matters pertaining specifically to their participation may be continued to a future agenda if needed or otherwise addressed.*

*Please be cautious and do not click on links in the chat area of the meeting unless you have verified they are safe. If you ever have questions about a link in a document purporting to be from Nevada Medicaid, please do not hesitate to contact [documentcontrol@dhcftp.nv.gov](mailto:documentcontrol@dhcftp.nv.gov) for verification.*

**Webinar:** <https://tinyurl.com/DHCFP2023PH>

Select "Join," enter your name and email and then select "Join."

The meeting should not require a password.

Audio Only: (775) 321-6111  
Conference ID: 934 453 822#

**PLEASE DO NOT PUT THIS NUMBER ON HOLD (*hang up and rejoin if you must take another call*)**

**YOU MAY BE UNMUTED BY THE HOST WHEN SEEKING PUBLIC COMMENT, PLEASE HANG UP AND REJOIN IF YOU ARE HAVING SIDE CONVERSATIONS DURING THE MEETING OR THOSE MAY BE HEARD BY OTHERS AND RECORDED**

**This meeting may be recorded to facilitate note-taking or other uses. By participating you consent to recording of your participation in this meeting.**

## AGENDA

1. General Public Comments (because of time considerations, the period for public comment by each speaker or organization may be limited to three minutes and speakers are urged to avoid repetition of comments made by previous speakers.)

2. **For possible action:** Discussion and adoption of changes to MSM Chapter 100 – Medicaid Program; and Addendum

Revisions to MSM Chapter 100 – Medicaid Program are being proposed to in its entirety. Changes to Addendum definitions for convicted, emergency medical condition, fiscal agent, medical director, and quality improvement organization (QIO-like) vendor is also being proposed.

**Entities Financially Affected:** All providers enrolled into Nevada Medicaid.

**Financial impact on local government:** No known fiscal impact on local government.

**Effective date:** April 25, 2023.

- a. Presentation of MSM Chapter 100 – Medicaid Program; and Addendum
- b. Public comment on proposed changes
- c. Adoption of proposed changes

3. **For possible action:** Discussion and adoption of changes to MSM Chapter 1200 – Prescribed Drugs, to reflect recommendations approved on January 19, 2023, by the Drug Utilization Review (DUR) Board and to add new clinical prior authorization criteria for Physician-Administered Drugs (PADs) The proposed changes include the adoption of new clinical prior authorization criteria for Nucala® (mepolizumab) and Dupixent® (dupilumab) for the treatment of Hypereosinophilic Syndrome (HES), Chronic Rhinosinusitis with Nasal Polyps, within the Respiratory and Allergy Biologics section; addition of new PAD-specific clinical prior authorization criteria for Ocrevus® (ocrelizumab) within the Multiple Sclerosis (MS) Agents section; addition of new clinical prior authorization criteria for penicillamine within the new Antirheumatics section; addition of new clinical prior authorization criteria for Rayaldee® (calcifediol) within the new Vitamins section; addition of new clinical prior authorization criteria for Relyvrio® (sodium phenylbutyrate/taurursodiol) within the new Amyotrophic Lateral Sclerosis (ALS) section; addition of new PAD prior authorization clinical criteria for Prolia® (denosumab) and Xgeva® (denosumab) within the Osteoporosis Agents section; addition of new PAD clinical prior authorization criteria within the Colony Stimulating Factors section; addition of new PAD clinical prior authorization criteria and quantity limits for Abraxane® (paclitaxel protein-bound particles) within the Taxane Chemotherapy Section; addition of PAD related prior authorization criteria and quantity limits for Bavencio® (avelumab) and Imfinzi® (durvalumab) within the Anti-PD-1 Monoclonal Antibodies section; addition of PAD related prior authorization criteria and quantity limits

for Beovu® (brolucizam-dbl) within the Ophthalmic-Macular Degeneration section; addition of PAD related prior authorization criteria and quantity limits for Avastin®, Myasi®, Zirabev™, Alysims®, Vegzelma™ (Bevacizumab) within the ANP-Human Vascular Endothelial Growth Factor Inhib Rec-MC Antibody; addition of PAD related prior authorization criteria and quantity limits for Darzalex® (daratumumab) within the Antineoplastic section; addition of PAD related prior authorization criteria and quantity limits for Darzalex Easpro® (daratumumab and hyaluronidase-fihj) within the Antineoplastic - CD38 Specific Recombinant Monoclonal Antibody Agent section; addition of PAD related prior authorization criteria and quantity limits for Elaprase® (idursulfase) within the Lysosomal Enzymes section; addition of PAD related prior authorization criteria and quantity limits for Eylea® (aflibercept) within the Anti-angiogenic ophthalmic agents section; addition of PAD related prior authorization criteria and quantity limits for Immune Globulins (immunoglobulin) within the Immune Globulins section; addition of new PAD related prior authorization criteria and quantity limits for Jemperli® (dostarlimab-gxly) and Keytruda® (pembrolizumab) within the Antineoplastic-Anti-Programmed Cell Death Receptor-1 (PD-1) section; addition of PAD related prior authorization criteria and quantity limits for Kadcyra® (adotrastuzumab emtansine) within the Antineoplastic-Antibody Drug Conjugates (ADCs) section; addition of PAD related prior authorization criteria and quantity limits for Aranesp® (darbepoetin alfa) within the Recombinant Human Erythropoietin's section; addition of PAD related prior authorization criteria and quantity limits for Pegfilgrastim/Colony Stimulating Factors within the Colony Stimulating Factors section.

**Entities Financially Affected:** Providers who prescribe, dispense or administer this drug may be affected by this change, including but not limited to the following Provider Types (PTs): Outpatient Surgery (PT 10); Hospital, Inpatient (PT 11); Hospital, Outpatient (PT 12); Intermediate Care Facilities for Individuals with Intellectual Disabilities, Public (PT 16); Special Clinics (PT 17); Nursing Facility (PT 19); Physician/Osteopath (PT 20); Podiatrist (PT 21); Advanced Practice Registered Nurse (PT 24); Pharmacy (PT 28); Home Health Agency (PT 29); Ambulatory Surgical Centers, Freestanding (PT 46); Indian Health Programs and Tribal Clinics (PT 47); Indian Health Service Hospital, Inpatient (Tribal) (PT 51), Indian Health Service Hospital, Outpatient (Tribal) (PT 52); Transitional Rehabilitative Center, Outpatient (PT 55); Inpatient Rehabilitation and Long Term Acute Care (LTAC) Specialty Hospitals (PT 56); Hospice (PT 64); Hospice, Long Term Care (PT 65); Intermediate Care Facilities for Individuals with Intellectual Disabilities, Private (PT 68); Nurse Anesthetist (PT 72); Critical Access Hospital (CAH), Inpatient (PT 75); Audiologist (PT 76); Physician's Assistant (PT 77); Indian Health Service Hospital, Inpatient (Non-Tribal) (PT 78); Indian Health Service Hospital, Outpatient (Non-Tribal) (PT 79).

**Financial impact on local government:** No known financial impact of local government.

**Effective date:** May 1, 2023.

- a. Presentation of MSM Chapter 1200
- b. Public comment on proposed changes
- c. Adoption of proposed changes

#### 4. Adjournment

---

**NOTE:** To use the long link to the meeting in the event there are issues with the URL shortener, please use the following complete link:

[https://teams.microsoft.com/l/meetup-join/19%3ameeting\\_OWIONGMzNTYtNDZhZi00NTA5LTlInzktNDMxNTczNjl2Y2Mz%40thread.v2/0?context=%7b%22Tid%22%3a%22e4a340e6-b89e-4e68-8eaa-1544d2703980%22%2c%22Oid%22%3a%22cc4c7a00-e2be-4dda-a27b-3405a8271b9c%22%7d](https://teams.microsoft.com/l/meetup-join/19%3ameeting_OWIONGMzNTYtNDZhZi00NTA5LTlInzktNDMxNTczNjl2Y2Mz%40thread.v2/0?context=%7b%22Tid%22%3a%22e4a340e6-b89e-4e68-8eaa-1544d2703980%22%2c%22Oid%22%3a%22cc4c7a00-e2be-4dda-a27b-3405a8271b9c%22%7d)

Nevada Medicaid is unaware of any financial impact to other entities or local government due to this public hearing, other than as stated above.

PLEASE NOTE: Items may be taken out of order. Items may be pulled or removed from the agenda at any time. All public comment will be limited to three minutes.

The DHCFP is exempt from Chapter 233B according to NRS 233B.039 and is not required to comply with the Nevada Administrative Procedure Act in this process. This meeting is conducted by and with state agency staff which is not a public body for purposes of NRS 241 related to Nevada Open Meeting Law, but every effort is made to be transparent in notice and information provided to encourage public awareness and participation.

This notice and agenda have been posted online at <http://dhcfp.nv.gov> and <http://notice.nv.gov>, as well as Carson City, Las Vegas, Elko, and Reno central offices for DHCFP. E-mail notice has been made to such individuals as have requested notice of meetings (to request notifications please contact [documentcontrol@dhcfp.nv.gov](mailto:documentcontrol@dhcfp.nv.gov), or at 1100 East William Street, Suite 101, Carson City, Nevada 89701.

DHCFP, 1100 E. William St., Suite 101, Carson City, Nevada 89701  
DHCFP, 1010 Ruby Vista Drive, Suite 103, Elko, Nevada 89801  
DHCFP, 1210 S. Valley View, Suite 104, Las Vegas, Nevada 89102  
DHCFP, 745 W. Moana Lane, Suite 200, Reno, Nevada 89509

If you require a physical copy of supporting material for the public meeting, please contact [documentcontrol@dhcfp.nv.gov](mailto:documentcontrol@dhcfp.nv.gov), or at 1100 East William Street, Suite 101, Carson City, Nevada 89701. Supporting material will also be posted online as referenced above.

Note: We are pleased to make reasonable accommodations for members of the public with a disability and wish to participate. If accommodated arrangements are necessary, notify DHCFP as soon as possible in advance of the meeting, by e-mail at [documentcontrol@dhcfp.nv.gov](mailto:documentcontrol@dhcfp.nv.gov) in writing, at 1100 East William Street, Suite 101, Carson City, Nevada 89701.